Retatrutide (GLP-3)
Next-generation triple receptor agonist. Phase 3 clinical research underway.
For research use only · Not for human consumption
Every source for Retatrutide (GLP-3)
Affiliate disclosure: purchases through links below may earn us a commission. Rankings are never sold — methodology · full disclosure
- ✓Third-party tested (Janoshik)
- ✓COAs provided — Per-batch core, quarterly bonus
- ✓Best $/mg in stock right now
- ✓4.8★ community rating
The research base
Phase 2 human trials demonstrate exceptional metabolic effects. 99%+ purity verified across batches in research-grade product.
How it works
Simultaneously activates GLP-1, GIP, and glucagon receptors. Triple-receptor synergy for metabolic optimization.
Common research protocols
Phase 2 trials titrated 2 → 4 → 8 → 12 mg/week over 24 weeks. GI side effects (nausea, occasional vomiting) peak with each dose increase. Heart rate elevation ~3-7 bpm at higher doses. Slow titration is essential — rapid escalation causes significant GI distress.
As a solo compound
Highly effective standalone compound. Triple-receptor agonism is its primary differentiator.
What to know
Common: GI adjustment, appetite reduction (intended effect). Well-tolerated in clinical trials.
Realistic expectations
Effects observed within 2-4 weeks; full metabolic adaptation 12+ weeks